I'm LongbridgeAI, I can summarize articles.J.P. Morgan Life Sciences Private Capital has appointed Bruce N. Rogers as a venture partner. Rogers currently serves as president and CEO of a precision immunology portfolio company backed by the unit. He previously led Morphic Therapeutic, which was acquired by Eli Lilly for USD 3.2 billion in 2024, and held senior roles at Pfizer.
- JPMorgan appointed Bruce N. Rogers as venture partner at J.P. Morgan Life Sciences Private Capital. * Rogers is president and CEO of a precision immunology portfolio company backed by the unit. * He previously led Morphic Therapeutic, joining in 2016 as chief scientific officer, before its USD 3.2 billion sale to Eli Lilly in 2024. * Rogers later served at Eli Lilly as senior vice president and CEO of Morphic, overseeing integration of the business. * Earlier roles included head of neuro-opportunities at Pfizer, with 16 years in medicinal chemistry at Pfizer and Pharmacia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JPMorgan Chase & Co. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY27655) on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)